<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160730</url>
  </required_header>
  <id_info>
    <org_study_id>Pro35720</org_study_id>
    <secondary_id>1R21DK103198-01</secondary_id>
    <nct_id>NCT02160730</nct_id>
  </id_info>
  <brief_title>Treatment of Cushing's Disease With R-roscovitine</brief_title>
  <official_title>Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shlomo Melmed, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor&#xD;
      ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.&#xD;
      To date, R-roscovitine has been evaluated in several Phase I and II studies and has shown&#xD;
      early signs of anti-cancer activity in approximately 240 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, R-roscovitine (seliciclib) has been evaluated in several Phase I and II studies and&#xD;
      has shown early signs of anti-cancer activity in approximately 240 patients. Studies included&#xD;
      a Phase I study in which single agent seliciclib was administered to patients with advanced&#xD;
      non-small cell lung cancer (NSCLC) and two Phase IIa studies in which seliciclib was&#xD;
      administered in combination with gemcitabine and cisplatin as first-line treatment and with&#xD;
      docetaxel as second-line treatment in NSCLC. Seliciclib was also evaluated in a Phase I study&#xD;
      in patients with nasopharyngeal cancer (NPC) with evidence of tumor shrinkage and concomitant&#xD;
      reduction in copy counts of the EBV virus that is causally associated with the pathogenesis&#xD;
      of NPC. Results from APPRAISE, a randomized discontinuation, double-blinded,&#xD;
      placebo-controlled, Phase IIb study of oral seliciclib capsules as a monotherapy in heavily&#xD;
      pretreated patients with NSCLC, demonstrated no difference between the seliciclib and placebo&#xD;
      arms in progression free survival but a substantial increase in overall survival was observed&#xD;
      (388 versus 218 days respectively (Cyclacel Pharmaceuticals press release Dec 21, 2010).&#xD;
      Here, the investigators propose an exploratory, proof of concept clinical trial to determine&#xD;
      if seliciclib can safely normalize urinary free cortisol levels by reducing pituitary&#xD;
      corticotroph tumor ACTH production in patients with Cushing disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    NIH grant ended.&#xD;
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. &quot;Normalizing&quot; is defined as having urine free cortisol levels within the normal range for that lab value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean HbA1c Levels Between Baseline and 4 Weeks</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>HbA1c levels are measured at baseline and at study end, these are averaged across all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Have a Visible Change in Tumor Size</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose at Baseline and 4 Weeks</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Mean change between baseline and week 4 of fasting blood glucose levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma ACTH at Baseline and 4 Weeks</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Mean change in Plasma ACTH between baseline and 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Symptoms</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Cortisol Between Baseline and 4 Weeks</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Mean serum cortisol values at baseline and 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Mean change in systolic blood pressure between baseline and 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Mean diastolic blood pressure between baseline and 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cushings Disease</condition>
  <arm_group>
    <arm_group_label>R-roscovitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-roscovitine</intervention_name>
    <description>See Arm Description</description>
    <arm_group_label>R-roscovitine</arm_group_label>
    <other_name>Seliciclib</other_name>
    <other_name>CYC202</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male and female patients at least 18 years old&#xD;
&#xD;
          -  Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH)&#xD;
             production:&#xD;
&#xD;
               -  Persistent hypercortisolemia established by two consecutive 24 h UFC levels at&#xD;
                  least 1.5x the upper limit of normal&#xD;
&#xD;
               -  Normal or elevated ACTH levels&#xD;
&#xD;
               -  Pituitary macroadenoma (&gt;1 cm) on MRI OR&#xD;
&#xD;
               -  Inferior Petrosal Sinus Sampling (IPSS) central to peripheral ACTH gradient &gt;2 at&#xD;
                  baseline and &gt;3 after CRH stimulation&#xD;
&#xD;
               -  Recurrent or persistent Cushing disease is defined as pathologically confirmed&#xD;
                  resected pituitary ACTH-secreting tumor, and 24 hour UFC above the upper limit of&#xD;
                  normal reference range beyond post-surgical week 6&#xD;
&#xD;
               -  Patients on medical treatment for Cushing's disease the following washout periods&#xD;
                  must be completed before screening assessments are performed:&#xD;
&#xD;
               -  Inhibitors of steroidogenesis (metyrapone, ketoconazole): 2 weeks&#xD;
&#xD;
               -  Somatostatin analogs (pasireotide): 2 weeks&#xD;
&#xD;
               -  Progesterone receptor antagonist (mifepristone): 2 weeks&#xD;
&#xD;
               -  Dopamine agonists (cabergoline): 4 weeks&#xD;
&#xD;
               -  CYP3A4 strong inducers or inhibitors: varies between drugs; minimum 5-6 times the&#xD;
                  half-life of drug&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with compromised visual fields, and not stable for at least 6 months&#xD;
&#xD;
          -  Patients with abutment or compression of the optic chiasm on MRI and normal visual&#xD;
             fields&#xD;
&#xD;
          -  Patients with Cushing's syndrome due to non-pituitary ACTH secretion&#xD;
&#xD;
          -  Patients with hypercortisolism secondary to adrenal tumors or nodular (primary)&#xD;
             bilateral adrenal hyperplasia&#xD;
&#xD;
          -  Patients who have a known inherited syndrome as the cause for hormone over secretion&#xD;
             (i.e. Carney Complex, McCune-Albright syndrome, MEN-1)&#xD;
&#xD;
          -  Patients with a diagnosis of glucocorticoid-remedial aldosteronism (GRA)&#xD;
&#xD;
          -  Patients with cyclic Cushing's syndrome defined by any measurement of UFC over the&#xD;
             previous 1 months within normal range&#xD;
&#xD;
          -  Patients with pseudo-Cushing's syndrome, i.e. non-autonomous hypercortisolism due to&#xD;
             overactivation of the HPA axis in uncontrolled depression, anxiety, obsessive&#xD;
             compulsive disorder, morbid obesity, alcoholism, and uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Patients who have undergone major surgery within 1 month prior to screening&#xD;
&#xD;
          -  Patients with serum K+&lt; 3.5 while on replacement treatment&#xD;
&#xD;
          -  Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C &gt;8%&#xD;
&#xD;
          -  Patients who have clinically significant impairment in cardiovascular function or are&#xD;
             at risk thereof, as evidenced by&#xD;
&#xD;
             - Congestive heart failure (NYHA Class III or IV), unstable angina, sustained&#xD;
             ventricular tachycardia, clinically significant bradycardia, high grade AV block,&#xD;
             history of acute MI less than one year prior to study entry&#xD;
&#xD;
          -  Patients with liver disease or history of liver disease such as cirrhosis, chronic&#xD;
             active hepatitis B and C, or chronic persistent hepatitis, or patients with ALT or AST&#xD;
             more than 1.5 x ULN, serum total bilirubin more than ULN, serum albumin less than 0.67&#xD;
             x LLN at screening&#xD;
&#xD;
          -  Serum creatinine &gt; 2 x ULN&#xD;
&#xD;
          -  Patients not biochemically euthyroid&#xD;
&#xD;
          -  Patients who have any current or prior medical condition that can interfere with the&#xD;
             conduct of the study or the evaluation of its results, such as&#xD;
&#xD;
               -  History of immunocompromise, including a positive HIV test result (Elisa and&#xD;
                  Western blot). An HIV test will not be required, however, previous medical&#xD;
                  history will be reviewed&#xD;
&#xD;
               -  Presence of active or suspected acute or chronic uncontrolled infection&#xD;
&#xD;
               -  History of, or current alcohol misuse/abuse in the 12 month period prior to&#xD;
                  screening&#xD;
&#xD;
          -  Female patients who are pregnant or lactating, or are of childbearing potential and&#xD;
             not practicing a medically acceptable method of birth control. If a woman is&#xD;
             participating in the trial then one form of contraception is sufficient (pill or&#xD;
             diaphragm) and the partner should use a condom. If oral contraception is used in&#xD;
             addition to condoms, the patient must have been practicing this method for at least&#xD;
             two months prior to screening and must agree to continue the oral contraceptive&#xD;
             throughout the course of the study and for 3 months after the study has ended. Male&#xD;
             patients who are sexually active are required to use condoms during the study and for&#xD;
             three month afterwards as a precautionary measure (available data do not suggest any&#xD;
             increased reproductive risk with the study drugs)&#xD;
&#xD;
          -  Patients who have participated in any clinical investigation with an investigational&#xD;
             drug within 1 month prior to screening or patients who have previously been treated&#xD;
             with seliciclib&#xD;
&#xD;
          -  Patients with any ongoing or likely to require additional concomitant medical&#xD;
             treatment to seliciclib for the tumor&#xD;
&#xD;
          -  Patients with concomitant treatment of strong CYP3A4 inducers or inhibitors.&#xD;
&#xD;
          -  Patients who were receiving mitotane and/or long-acting somatostatin analogs&#xD;
             (octreotide LAR or lanreotide)&#xD;
&#xD;
          -  Patients who were receiving pasireotide or ketoconazole before study entry must&#xD;
             complete a 2 week washout period prior to receiving seliciclib&#xD;
&#xD;
          -  Patients who have received pituitary irradiation within the last 5 years prior to the&#xD;
             baseline visit&#xD;
&#xD;
          -  Patients who have been treated with radionuclide at any time prior to study entry&#xD;
&#xD;
          -  Patients with known hypersensitivity to seliciclib&#xD;
&#xD;
          -  Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will be unable to complete the entire study&#xD;
&#xD;
          -  Patients with presence of Hepatitis B surface antigen (HbsAg)&#xD;
&#xD;
          -  Patients with presence of Hepatitis C antibody test (anti-HCV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shlomo Melmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ning-Ai Liu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. doi: 10.1210/jc.2008-0125. Epub 2008 Mar 11.</citation>
    <PMID>18334580</PMID>
  </reference>
  <reference>
    <citation>Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62. doi: 10.1210/jc.2007-2734. Epub 2008 Apr 15. Review.</citation>
    <PMID>18413427</PMID>
  </reference>
  <reference>
    <citation>Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug;98(8):3446-53. doi: 10.1210/jc.2013-1771. Epub 2013 Jun 3.</citation>
    <PMID>23733372</PMID>
  </reference>
  <reference>
    <citation>Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012 Jun;97(6):2039-49. doi: 10.1210/jc.2011-3350. Epub 2012 Mar 30.</citation>
    <PMID>22466348</PMID>
  </reference>
  <reference>
    <citation>Melmed S. Pathogenesis of pituitary tumors. Nature reviews Endocrinology. 2011;7(5):257-66. Epub 2011/03/23. doi: 10.1038/nrendo.2011.40. PubMed PMID: 21423242.</citation>
  </reference>
  <reference>
    <citation>Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol. 2009 Feb;42(2):75-86. doi: 10.1677/JME-08-0146. Epub 2008 Nov 5. Review.</citation>
    <PMID>18987159</PMID>
  </reference>
  <reference>
    <citation>Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol. 2000 Jul;143(1):R1-6.</citation>
    <PMID>10870044</PMID>
  </reference>
  <reference>
    <citation>Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell. 2000 Mar 31;101(1):79-89.</citation>
    <PMID>10778858</PMID>
  </reference>
  <reference>
    <citation>Geng Y, Eaton EN, Picón M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene. 1996 Mar 21;12(6):1173-80.</citation>
    <PMID>8649818</PMID>
  </reference>
  <reference>
    <citation>Sengupta T, Abraham G, Xu Y, Clurman BE, Minella AC. Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis. Mol Cell Biol. 2011 Sep;31(18):3885-95. doi: 10.1128/MCB.05089-11. Epub 2011 Jul 11.</citation>
    <PMID>21746877</PMID>
  </reference>
  <reference>
    <citation>Minella AC, Loeb KR, Knecht A, Welcker M, Varnum-Finney BJ, Bernstein ID, Roberts JM, Clurman BE. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev. 2008 Jun 15;22(12):1677-89. doi: 10.1101/gad.1650208.</citation>
    <PMID>18559482</PMID>
  </reference>
  <reference>
    <citation>Kossatz U, Breuhahn K, Wolf B, Hardtke-Wolenski M, Wilkens L, Steinemann D, Singer S, Brass F, Kubicka S, Schlegelberger B, Schirmacher P, Manns MP, Singer JD, Malek NP. The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J Clin Invest. 2010 Nov;120(11):3820-33. doi: 10.1172/JCI41959. Epub 2010 Oct 11.</citation>
    <PMID>20978349</PMID>
  </reference>
  <reference>
    <citation>Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4089-94. Epub 2007 Feb 27.</citation>
    <PMID>17360482</PMID>
  </reference>
  <reference>
    <citation>Loeb KR, Kostner H, Firpo E, Norwood T, D Tsuchiya K, Clurman BE, Roberts JM. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell. 2005 Jul;8(1):35-47.</citation>
    <PMID>16023597</PMID>
  </reference>
  <reference>
    <citation>Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D, Brue T, Drouin J. Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol. 2010 Sep;24(9):1835-45. doi: 10.1210/me.2010-0091. Epub 2010 Jul 21.</citation>
    <PMID>20660298</PMID>
  </reference>
  <reference>
    <citation>Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, Drouin J. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 2006 Oct 15;20(20):2871-86.</citation>
    <PMID>17043312</PMID>
  </reference>
  <reference>
    <citation>Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8414-9. doi: 10.1073/pnas.1018091108. Epub 2011 May 2.</citation>
    <PMID>21536883</PMID>
  </reference>
  <reference>
    <citation>Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev. 2007 Apr;28(2):165-86. Epub 2007 Feb 26. Review.</citation>
    <PMID>17325339</PMID>
  </reference>
  <reference>
    <citation>Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997 Apr;11(4):433-41.</citation>
    <PMID>9092795</PMID>
  </reference>
  <reference>
    <citation>Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503. doi: 10.1073/pnas.0804810105. Epub 2008 Nov 3.</citation>
    <PMID>18981426</PMID>
  </reference>
  <reference>
    <citation>Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, Toledano Y, Tong Y, Kovacs K, Scheithauer B, Melmed S. Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One. 2011 Mar 25;6(3):e17924. doi: 10.1371/journal.pone.0017924.</citation>
    <PMID>21464964</PMID>
  </reference>
  <reference>
    <citation>Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907. Review.</citation>
    <PMID>19568282</PMID>
  </reference>
  <reference>
    <citation>Legraverend M, Grierson DS. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Bioorg Med Chem. 2006 Jun 15;14(12):3987-4006. Epub 2006 Feb 24. Review.</citation>
    <PMID>16503144</PMID>
  </reference>
  <reference>
    <citation>Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001 Mar 23;104(6):849-59.</citation>
    <PMID>11290323</PMID>
  </reference>
  <reference>
    <citation>Wesierska-Gadek J, Krystof V. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia? Ann N Y Acad Sci. 2009 Aug;1171:228-41. doi: 10.1111/j.1749-6632.2009.04726.x. Review.</citation>
    <PMID>19723060</PMID>
  </reference>
  <reference>
    <citation>Siegel-Lakhai Wea. ASCO Proceedings, Abs 2060. 2005.</citation>
  </reference>
  <reference>
    <citation>Yeo et al. J Clin Oncol 2009 27-15s (Suppl abstr 6026).</citation>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <results_first_submitted>September 23, 2021</results_first_submitted>
  <results_first_submitted_qc>October 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2021</results_first_posted>
  <disposition_first_submitted>September 25, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 8, 2019</disposition_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Shlomo Melmed, MD</investigator_full_name>
    <investigator_title>Sr. Vice President of Academic Affairs</investigator_title>
  </responsible_party>
  <keyword>Cushings disease</keyword>
  <keyword>R-roscovitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Roscovitine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02160730/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Main ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02160730/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: HIPAA</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02160730/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Appendix for International Subjects</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02160730/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients on medical treatment for CD must complete washout periods before screening assessments are performed: Inhibitors of steroidogenesis (metyrapone, ketoconazole): 2 weeks; somatostatin receptor ligand (SRL; pasireotide): short-acting, 2 weeks; long active, 4 weeks; progesterone receptor antagonist (mifepristone): 2 weeks; dopamine agonists (cabergoline): 4 weeks; CYP3A4 strong inducers or inhibitors: varies between drugs, minimum 5-6 x the drug half-life.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>R-roscovitine</title>
          <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R-roscovitine</title>
          <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Mean Urine Free Cortisol (mcg/24hr)</title>
          <units>mcg/24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233.3" spread="108.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks</title>
        <description>To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. &quot;Normalizing&quot; is defined as having urine free cortisol levels within the normal range for that lab value.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.&#xD;
R-roscovitine: See Arm Description</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks</title>
          <description>To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. &quot;Normalizing&quot; is defined as having urine free cortisol levels within the normal range for that lab value.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean HbA1c Levels Between Baseline and 4 Weeks</title>
        <description>HbA1c levels are measured at baseline and at study end, these are averaged across all subjects.</description>
        <time_frame>Baseline, 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean HbA1c Levels Between Baseline and 4 Weeks</title>
          <description>HbA1c levels are measured at baseline and at study end, these are averaged across all subjects.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study End-4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Have a Visible Change in Tumor Size</title>
        <description>A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Have a Visible Change in Tumor Size</title>
          <description>A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia</title>
        <description>The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia</title>
          <description>The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose at Baseline and 4 Weeks</title>
        <description>Mean change between baseline and week 4 of fasting blood glucose levels.</description>
        <time_frame>Baseline, 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose at Baseline and 4 Weeks</title>
          <description>Mean change between baseline and week 4 of fasting blood glucose levels.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.4" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma ACTH at Baseline and 4 Weeks</title>
        <description>Mean change in Plasma ACTH between baseline and 4 weeks.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma ACTH at Baseline and 4 Weeks</title>
          <description>Mean change in Plasma ACTH between baseline and 4 weeks.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Symptoms</title>
        <description>Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Symptoms</title>
          <description>Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks.</description>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217" spread="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.4" spread="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Cortisol Between Baseline and 4 Weeks</title>
        <description>Mean serum cortisol values at baseline and 4 weeks</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Cortisol Between Baseline and 4 Weeks</title>
          <description>Mean serum cortisol values at baseline and 4 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Mean change in systolic blood pressure between baseline and 4 weeks.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Mean change in systolic blood pressure between baseline and 4 weeks.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.3" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <description>Mean diastolic blood pressure between baseline and 4 weeks.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-roscovitine</title>
            <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <description>Mean diastolic blood pressure between baseline and 4 weeks.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening through 1 week after last dose, up to 5 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>R-roscovitine</title>
          <description>• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine Levels</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ning-Ai Liu</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-423-7382</phone>
      <email>ning-ai.liu@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

